Ethics of Early Intervention in Alzheimer's Disease
- PMID: 33769219
- DOI: 10.1080/21507740.2021.1896595
Ethics of Early Intervention in Alzheimer's Disease
Abstract
Alzheimer's disease (AD) research, treatment, and prevention focus increasingly on developing personalized interventions based on personal genetic, biological, phenotypic data, for early intervention (EI) to limit harm. This approach has much to recommend it, but important ethical and philosophical challenges follow that should be considered, which we analyze here. We argue that advancing understanding of the causes of AD undermines the clarity of the distinction between primary and secondary prevention. This makes it increasingly unclear how primary and secondary categories can be appealed to as the basis for making judgements about what interventions are permissible, and for distinguishing between acceptably vs unacceptably early points in life to intervene. Timely efforts at prevention are vital for limiting harm from AD and given the logic of EI is that, in presence of risk, earlier is better, one might assume that earliest is best. This may or may not be the case; however, the permissibility of intervening in different ways at different stages of life is complex and turns on numerous contextual factors. We consider the particular ethical implications of intervening at different points in the life course, presenting a valuable resource for negotiating clinical and policy implications of EI in AD.
Keywords: Dementia; bioethics; brain; epistemology; neuroethics; psychiatry.
Comment in
-
Prophylactic Amyloidectomy? Reasons for Caution in Moving to Biomarker-Based Dementia Interventions in Asymptomatic Individuals.AJOB Neurosci. 2021 Oct-Dec;12(4):248-250. doi: 10.1080/21507740.2021.1949758. AJOB Neurosci. 2021. PMID: 34704896 No abstract available.
-
Critical Need for Inclusion of Under-Served Minorities in the Emerging Clinical Landscape for Alzheimer's Disease.AJOB Neurosci. 2021 Oct-Dec;12(4):253-256. doi: 10.1080/21507740.2021.1941399. AJOB Neurosci. 2021. PMID: 34704897 No abstract available.
-
Personal Utility and Early Intervention in Alzheimer's Disease.AJOB Neurosci. 2021 Oct-Dec;12(4):226-228. doi: 10.1080/21507740.2021.1941411. AJOB Neurosci. 2021. PMID: 34704901 No abstract available.
-
Dementia Risk Reduction in Mid-Life: The Real Ethical Challenge.AJOB Neurosci. 2021 Oct-Dec;12(4):250-253. doi: 10.1080/21507740.2021.1941401. AJOB Neurosci. 2021. PMID: 34704902 No abstract available.
-
The Need for Preservation of Medical Decision Making with Diminished Cognitive Capacity.AJOB Neurosci. 2021 Oct-Dec;12(4):224-226. doi: 10.1080/21507740.2021.1941412. AJOB Neurosci. 2021. PMID: 34704903 No abstract available.
-
(Un)Ethical Early Interventions in the Alzheimer's "Marketplace of Memory".AJOB Neurosci. 2021 Oct-Dec;12(4):245-247. doi: 10.1080/21507740.2021.1941402. AJOB Neurosci. 2021. PMID: 34704904 No abstract available.
-
Early Diagnosis of Alzheimer's Disease - Blessing or Curse for Patients?AJOB Neurosci. 2021 Oct-Dec;12(4):234-236. doi: 10.1080/21507740.2021.1943051. AJOB Neurosci. 2021. PMID: 34704907 No abstract available.
-
Early Detection of AD Biomarkers and the Ethical Criteria for Screening Programs.AJOB Neurosci. 2021 Oct-Dec;12(4):231-233. doi: 10.1080/21507740.2021.1941407. AJOB Neurosci. 2021. PMID: 34704908 No abstract available.
-
Stop the Madness: Dementia, "Radical Medicalization," and Straw Men.AJOB Neurosci. 2021 Oct-Dec;12(4):229-231. doi: 10.1080/21507740.2021.1941408. AJOB Neurosci. 2021. PMID: 34704909 No abstract available.
-
Early Detection of Alzheimer's Disease Benefits Research, Quality of Life, and End-of-Life Planning.AJOB Neurosci. 2021 Oct-Dec;12(4):243-244. doi: 10.1080/21507740.2021.1941404. AJOB Neurosci. 2021. PMID: 34704912 No abstract available.
-
Shifting the Focus of Dementia Prevention: Ethical Considerations.AJOB Neurosci. 2021 Oct-Dec;12(4):240-242. doi: 10.1080/21507740.2021.1941405. AJOB Neurosci. 2021. PMID: 34704913 No abstract available.
-
Deep Brain Stimulation for Preclinical and Prodromal Alzheimer's Disease: Integrating Beneficence, Non-Maleficence, and Autonomy Considerations Through Responsible Innovation.AJOB Neurosci. 2021 Oct-Dec;12(4):236-239. doi: 10.1080/21507740.2021.1941406. AJOB Neurosci. 2021. PMID: 34704914 No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical